Clinical Trials

Sponsor: ADC Therapeutics SA

Sponsor Study ID: ADCT-402-311

Study Title: Phase 3 Study of Loncastuximab Tesirine, an Anti-CD-19 Antibody-Drug Conjugate, in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

NCT Number: NCT04384484

Phase: III

Protocol Type: Treatment

Age Group: Adult

Disease Sites: Non-Hodgkin's Lymphoma

Study Objectives: The purpose of this study is to evaluate the efficacy of loncastuximab tesirine (ADCT-402) combined with rituximab compared to standard immunochemotherapy.

If you would like to contact a MUSC study team member to learn more information about this study, click HERE.